Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04259086 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
A Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 8
- Study locations
NCT04259086 is a Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) that has completed, run by Revance Therapeutics. The registered enrollment target is 48 participants. The trial reports 8 study locations across 6 states.
The verdict
NCT04259086, a Phase 2 study of Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
Interventions
- DRUG DaxibotulinumtoxinA for injection
Study Locations (8)
California
- Site 1 - Manhattan Beach
- Site 3 - San Diego
- Site 7 - Santa Monica
Florida
- Site 5 - Coral Gables
Massachusetts
- Site 2 - Chestnut Hill
New York
- Site 6 - New York
British Columbia
- Site 4 - Vancouver
Ontario
- Site 8 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04259086
The ClinicalTrials.gov registry entry for NCT04259086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) appearing as the primary indexed condition, and to 1 intervention - of which DaxibotulinumtoxinA for injection is the first listed.
NCT04259086 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04259086 about?
NCT04259086 is a clinical study titled "Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines". This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
What is the current status of trial NCT04259086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-12-06. Estimated completion is 2020-11-02.
What conditions does trial NCT04259086 study?
This clinical trial studies the following conditions: Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines).
What interventions are being tested in trial NCT04259086?
The interventions under investigation include: DaxibotulinumtoxinA for injection (DRUG).
Who is sponsoring clinical trial NCT04259086?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04259086 being conducted?
This trial has 8 study locations across California, Florida, Massachusetts, New York, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.